Petros Pharmaceuticals, Inc. (NASDAQ:PTPI), a leading provider of therapeutics for men's health, announces today the expansion of its program for investigational H100, a novel patented non-invasive topical
Petros Pharmaceuticals Inc (NASDAQ: PTPI) is trading higher Wednesday after the company announced 476% growth year-over-year of STENDRA tablet sales as part of its digital marketing agreement with Hims & Hers Health Inc (NYSE: